These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30204055)

  • 61. Tankyrase inhibitors as therapeutic targets for cancer.
    Kamal A; Riyaz S; Srivastava AK; Rahim A
    Curr Top Med Chem; 2014; 14(17):1967-76. PubMed ID: 25262803
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Exploration of the nicotinamide-binding site of the tankyrases, identifying 3-arylisoquinolin-1-ones as potent and selective inhibitors in vitro.
    Paine HA; Nathubhai A; Woon EC; Sunderland PT; Wood PJ; Mahon MF; Lloyd MD; Thompson AS; Haikarainen T; Narwal M; Lehtiö L; Threadgill MD
    Bioorg Med Chem; 2015 Sep; 23(17):5891-908. PubMed ID: 26189030
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor.
    Karlberg T; Markova N; Johansson I; Hammarström M; Schütz P; Weigelt J; Schüler H
    J Med Chem; 2010 Jul; 53(14):5352-5. PubMed ID: 20565110
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Exploring the Effects of Chirality of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl) phenyl]imidazolidine-2,4-dione and its Derivatives on the Oncological Target Tankyrase 2. Atomistic Insights.
    Quintina Peters X; Poonan P; Salifu Yakubu E; Issa Alahmdi M; Abo-Dya NE; Soliman M
    Curr Pharm Biotechnol; 2023 Mar; ():. PubMed ID: 37005548
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Human Cytomegalovirus Inhibits the PARsylation Activity of Tankyrase--A Potential Strategy for Suppression of the Wnt Pathway.
    Roy S; Liu F; Arav-Boger R
    Viruses; 2015 Dec; 8(1):. PubMed ID: 26729153
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Structural basis of selective inhibition of human tankyrases.
    Narwal M; Venkannagari H; Lehtiö L
    J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
    Lakshmi TV; Bale S; Khurana A; Godugu C
    Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeting Tankyrase to Fight WNT-dependent Tumours.
    Thorvaldsen TE
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):81-88. PubMed ID: 28371398
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identification by Inverse Virtual Screening of magnolol-based scaffold as new tankyrase-2 inhibitors.
    Di Micco S; Pulvirenti L; Bruno I; Terracciano S; Russo A; Vaccaro MC; Ruggiero D; Muccilli V; Cardullo N; Tringali C; Riccio R; Bifulco G
    Bioorg Med Chem; 2018 Aug; 26(14):3953-3957. PubMed ID: 29934219
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities.
    Zamudio-Martinez E; Herrera-Campos AB; Muñoz A; Rodríguez-Vargas JM; Oliver FJ
    J Exp Clin Cancer Res; 2021 Apr; 40(1):144. PubMed ID: 33910596
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.
    Bregman H; Gunaydin H; Gu Y; Schneider S; Wilson C; DiMauro EF; Huang X
    J Med Chem; 2013 Feb; 56(3):1341-5. PubMed ID: 23316926
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tankyrase Inhibitor for Cardiac Tissue Regeneration: an
    Hosseini FS; Amanlou A; Amanlou M
    Iran J Pharm Res; 2021; 20(4):315-328. PubMed ID: 35194449
    [TBL] [Abstract][Full Text] [Related]  

  • 73. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.
    Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L
    ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The zinc-binding motif in tankyrases is required for the structural integrity of the catalytic ADP-ribosyltransferase domain.
    Sowa ST; Lehtiö L
    Open Biol; 2022 Mar; 12(3):210365. PubMed ID: 35317661
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Solution NMR assignment of the ARC4 domain of human tankyrase 2.
    Zaleska M; Pollock K; Collins I; Guettler S; Pfuhl M
    Biomol NMR Assign; 2019 Apr; 13(1):255-260. PubMed ID: 30847846
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Context-Dependent Role for the RNF146 Ubiquitin Ligase in Wingless/Wnt Signaling in
    Wang Z; Tacchelly-Benites O; Noble GP; Johnson MK; Gagné JP; Poirier GG; Ahmed Y
    Genetics; 2019 Mar; 211(3):913-923. PubMed ID: 30593492
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.
    Johannes JW; Almeida L; Barlaam B; Boriack-Sjodin PA; Casella R; Croft RA; Dishington AP; Gingipalli L; Gu C; Hawkins JL; Holmes JL; Howard T; Huang J; Ioannidis S; Kazmirski S; Lamb ML; McGuire TM; Moore JE; Ogg D; Patel A; Pike KG; Pontz T; Robb GR; Su N; Wang H; Wu X; Zhang HJ; Zhang Y; Zheng X; Wang T
    ACS Med Chem Lett; 2015 Mar; 6(3):254-9. PubMed ID: 25815142
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1.
    Deng Z; Atanasiu C; Zhao K; Marmorstein R; Sbodio JI; Chi NW; Lieberman PM
    J Virol; 2005 Apr; 79(8):4640-50. PubMed ID: 15795250
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Time-Domain Analysis of Molecular Dynamics Trajectories Using Deep Neural Networks: Application to Activity Ranking of Tankyrase Inhibitors.
    Berishvili VP; Perkin VO; Voronkov AE; Radchenko EV; Syed R; Venkata Ramana Reddy C; Pillay V; Kumar P; Choonara YE; Kamal A; Palyulin VA
    J Chem Inf Model; 2019 Aug; 59(8):3519-3532. PubMed ID: 31276400
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development and structural analysis of adenosine site binding tankyrase inhibitors.
    Haikarainen T; Waaler J; Ignatev A; Nkizinkiko Y; Venkannagari H; Obaji E; Krauss S; Lehtiö L
    Bioorg Med Chem Lett; 2016 Jan; 26(2):328-333. PubMed ID: 26706174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.